Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.64 |
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | SLC2A1 | P11166 | 3/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1409464 | 0.89 | SMN1; SMN2 (0.70) | POLBSMN1; SMN2L3MBTL1TSHRALDH1A1 | |
| SCHEMBL2933630 | 0.84 | SIGMAR1 (0.63) | POLBSIGMAR1SMN1; SMN2SLC2A1L3MBTL1 | |
| SCHEMBL20248784 | 0.78 | POLB (0.96) | POLBSIGMAR1SMN1; SMN2L3MBTL1TSHR | |
| SCHEMBL270734 | 0.77 | SIGMAR1 (1.00) | POLBSIGMAR1SMN1; SMN2L3MBTL1TSHR | |
| SCHEMBL30309662 | 0.77 | CA1 (0.61) | SMN1; SMN2CA1CA2ALDH1A1 | |
| SCHEMBL16735334 | 0.77 | CA1 (0.61) | SMN1; SMN2CA1CA2ALDH1A1 | |
| SCHEMBL19869958 | 0.76 | GAA (0.61) | POLBSIGMAR1SMN1; SMN2CA1CA2 | |
| SCHEMBL16118202 | 0.76 | CA1 (0.59) | POLBSMN1; SMN2CA1CA2TSHR | |
| SCHEMBL2498510 | 0.76 | L3MBTL1 (0.81) | POLBSIGMAR1SMN1; SMN2L3MBTL1TSHR | |
| SCHEMBL16098346 | 0.75 | CA1 (0.66) | SMN1; SMN2CA1CA2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2044051-B1 | PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS | BIOVITRUM AB PUBL (SE) | 2010-01-27 | — | — | EP | disclosed |
| EP-2044051-A1 | PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS | BIOVITRUM AB (publ) (SE) | 2009-04-08 | — | — | EP | disclosed |
| US-20080039450-A1 | Compounds | BIOVITRUM AB (PUBL.) (SE) | 2008-02-14 | — | — | US | disclosed |
| WO-2007147874-A1 | PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS | BIOVITRUM AB (PUBL) (SE) | 2007-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039450-A1 | Compounds | NEK2, CSNK2A3, CSNK2A1 | POLB 1721/4885SIGMAR1 1647/4885SMN1; SMN2 567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.